The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Responses to romidepsin by line of therapy in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL).
Francine M. Foss
Consultant or Advisory Role - Celgene; Eisai; Kyowa Hakko Kirin; Seattle Genetics; Spectrum Pharmaceuticals
Honoraria - Celgene; Spectrum Pharmaceuticals
Research Funding - Celgene
Barbara Pro
Consultant or Advisory Role - Celgene
Honoraria - Celgene
H. Miles Prince
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Lubomir Sokol
Consultant or Advisory Role - Celgene (U)
Research Funding - Gloucester Pharmaceuticals
Matthew Greenwood
No relevant relationships to disclose
Dolores Caballero
No relevant relationships to disclose
Steven M. Horwitz
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Millennium
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Millennium
Research Funding - Celgene; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Millennium; Seattle Genetics; Spectrum Pharmaceuticals
Bertrand Coiffier
Consultant or Advisory Role - Celgene